BiliLED low cost neonatal phototherapy, from prototype to industry
Resumen:
BiliLED is a phototherapy instrument designed to reduce bilirrubin blood rates in new born babies with jaundice. The light source is centred at 470 nm with a bandwidth of 35 nm and includes a matrix of 196 (14x14) InGaN LEDs. The optical elements are designed to maximize the light intensity useful for treatment, with a small number of LEDs in a compact and low cost unit. The optic array is such that every LED illuminates all the treatment area, which ensures redundancy and, thus, a high reliability not to be found in single-lamp instruments. Thermal dissipation and cost of BiliLED are both an order-of-magnitude smaller than conventional therapy lamps. BiliLED adjusts coetaneous irradiation with a feedback loop to compensate the loss or aging of LEDs achieving a calibrated light source for over a decade of use. A clinical trial in 20 hyperbilirrubinaemia patients shows 16% bilirrubin degradation within 24 hours of treatment, higher than most lamp phototherapy instruments. The steps from prototype to commercial model are described.
2007 | |
Inglés | |
Universidad de la República | |
COLIBRI | |
https://hdl.handle.net/20.500.12008/38781 | |
Acceso abierto | |
Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0) |
Sumario: | BiliLED is a phototherapy instrument designed to reduce bilirrubin blood rates in new born babies with jaundice. The light source is centred at 470 nm with a bandwidth of 35 nm and includes a matrix of 196 (14x14) InGaN LEDs. The optical elements are designed to maximize the light intensity useful for treatment, with a small number of LEDs in a compact and low cost unit. The optic array is such that every LED illuminates all the treatment area, which ensures redundancy and, thus, a high reliability not to be found in single-lamp instruments. Thermal dissipation and cost of BiliLED are both an order-of-magnitude smaller than conventional therapy lamps. BiliLED adjusts coetaneous irradiation with a feedback loop to compensate the loss or aging of LEDs achieving a calibrated light source for over a decade of use. A clinical trial in 20 hyperbilirrubinaemia patients shows 16% bilirrubin degradation within 24 hours of treatment, higher than most lamp phototherapy instruments. The steps from prototype to commercial model are described. |
---|